EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS
Acquired by
PERKINELMER
EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS acquired by PERKINELMER
Target
EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS
Acquirer
PERKINELMER
Context
PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally. The strategic rationale includes leveraging EUROIMMUN’s high-growth profile (averaging 19% revenue growth over five years) to accelerate PerkinElmer’s overall earnings. Additionally, the acquisition allows PerkinElmer to drive EUROIMMUN’s specialized solutions through its well-established U.S. commercial channels.
EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS, which reported an EBITDA margin of LOGIN in 2017, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
EUROIMMUN is a global leader in autoimmune testing and an emerging provider of infectious disease and allergy diagnostics. Headquartered in Europe, the organization leverages deep expertise across immunology, cell biology, biochemistry, and molecular biology to develop advanced detection technologies. It manufactures high-quality diagnostic reagents and instruments used by medical laboratories worldwide to accurately identify antibodies and diagnose a wide array of conditions. Boasting a massive international footprint, the enterprise generates the vast majority of its revenue overseas, particularly across Asian and EMEA markets, serving customers in dozens of countries. Supported by a large global workforce and a decades-long history of continuous scientific innovation, the firm stands as a premier technological pillar in the specialized in-vitro diagnostics sector.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.